VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 9 Publications

3 Customer Reviews

  • J Invest Dermatol, 2018, 138(6):1380-1390. VX-702 purchased from Selleck.

    Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

  •  Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{\XcGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTV2MzFOwG0> MYDTRW5ITVJ?
human NCI-H720 cell NYnHcIpYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mmj3TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF4OEKg{txO MUTTRW5ITVJ?
JVM-2 cell NWPZN3BxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlfTTY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFg{KM7:TR?= Mn7qV2FPT0WU
human NCI-H69 cell M1;jWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmrsTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSE[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xQTl2MTFOwG0> NUfiXW52W0GQR1XS
human BV-173 cell NGru[VNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE{QDZizszN M3nOUXNCVkeHUh?=
human KU812 cell NYDtXIpqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNlQ5QCEQvF2= NXzETG82W0GQR1XS
human DU-145 cell MmryS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfBTY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE1PTV2IN88US=> MlPYV2FPT0WU
KARPAS-45 cell NELVNFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH7XSHdKdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUS4NlYh|ryP NEHiWlBUSU6JRWK=
human AGS cell M4j2V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mo\GTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG1NlUyKM7:TR?= NGKwVpVUSU6JRWK=
human MOLT-13 cell NHTnZ3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYPxSFFZUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNUm4NUDPxE1? NXnzZW4zW0GQR1XS
human NCI-H209 cell MlfQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1y3dGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5NUig{txO NYr1cGdpW0GQR1XS
human CTV-1 cell NEWzPHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWC5SYZTUW6qaXLpeIlwdiCxZjDoeY1idiCFVG[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTh|OEmg{txO NEC5NphUSU6JRWK=
LU-139 cell NXPifVAyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoLMTY5pcWKrdHnvckBw\iCqdX3hckBNXS1zM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE6PDN3IN88US=> MX3TRW5ITVJ?
ML-2 cell NFX2TGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1NNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyOlYyKM7:TR?= NYXaW|l2W0GQR1XS
human K5 cell MmXLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2jYXWlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyPVE4KM7:TR?= NEXMOFBUSU6JRWK=
human SBC-1 cell NIruVWNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mlj3TY5pcWKrdHnvckBw\iCqdX3hckBUSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlM3OiEQvF2= MUXTRW5ITVJ?
human COR-L88 cell MnmzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnuRXdKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|NEig{txO MYXTRW5ITVJ?
human KY821 cell Ml3US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX\KO3VkUW6qaXLpeIlwdiCxZjDoeY1idiCNWUiyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl4MEOg{txO M4e3V3NCVkeHUh?=
human HCC2218 cell Mo\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUjwbHJoUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNlE5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52OUeyPEDPxE1? MV7TRW5ITVJ?
human ECC10 cell NV;BS3RET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVrJcohq[mm2aX;uJI9nKGi3bXHuJGVESzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OVM5QSEQvF2= MYPTRW5ITVJ?
human EW-3 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MljlTY5pcWKrdHnvckBw\iCqdX3hckBGXy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OlYyOSEQvF2= MnLIV2FPT0WU
human EW-18 cell M2PmSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PF[2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc1Pjd7IN88US=> NF2zW4NUSU6JRWK=
human UACC-257 cell NVHC[XpiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTX[FhKdmirYnn0bY9vKG:oIHj1cYFvKFWDQ1OtNlU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{MEOyOkDPxE1? MVXTRW5ITVJ?
human G-361 cell NEfu[|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn3xTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFk2OTlizszN NIrkdIRUSU6JRWK=
human HMV-II cell NHe5RpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEXJ[otKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO MX;TRW5ITVJ?
human DEL cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMkC3NFQh|ryP MkT2V2FPT0WU
human IGROV-1 cell M1z1Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVfJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{OTh6IN88US=> NWX5S4JSW0GQR1XS
human SK-OV-3 cell MmrpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4XJfmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPjF4OUeg{txO NGrl[npUSU6JRWK=
human LAMA-84 cell Mn7XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkWxTY5pcWKrdHnvckBw\iCqdX3hckBNSU2DLUi0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44OTJ6NDFOwG0> MWLTRW5ITVJ?
human NCI-H510A cell MnzVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XCcGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi57MkWyOkDPxE1? NVHnc45GW0GQR1XS
human CP66-MEL cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGNRPjZvTVXMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk46OzV3OTFOwG0> MmLQV2FPT0WU
human HAL-01 cell Mke1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUnoW5NvUW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ5OUG4JO69VQ>? MUPTRW5ITVJ?
human RS4-11 cell  NEK4[FlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF3KSldKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzB3N{Og{txO M3XHNHNCVkeHUh?=
human RPMI-8226 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYjkSYZbUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVgzOjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkiyN|c3KM7:TR?= M{O5eHNCVkeHUh?=
human NCI-H82 cell NFfZWJBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HweWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQDl|MEWg{txO M3zqPXNCVkeHUh?=
human NY cells NXLUPVM5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVfPZ2ZyUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlc3OzdizszN M3nXc3NCVkeHUh?=
human MDA-MB-361 cell Ml;qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYK0TJlqUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60N|E2QCEQvF2= NYXxU21jW0GQR1XS
human MOLT-4 cell NGrPTGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXPob5M{UW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7MUmzJO69VQ>? NGHzOZRUSU6JRWK=
human DU-4475 cell M4\k[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVXJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA2PTZ3IN88US=> NWjwPZBEW0GQR1XS
human ESS-1 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yPVE4QSEQvF2= MVvTRW5ITVJ?
human NCI-H1299 cell MnH3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEfVRmpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVI6QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUOwN|Mh|ryP NFOyRVRUSU6JRWK=
human COLO-684 cell NX2xbJhNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoXMTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPThzNkWg{txO MX\TRW5ITVJ?
human MV-4-11 cell MnHKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWXlcZVIUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS55MUG5PUDPxE1? M1LUfnNCVkeHUh?=
human D-542MG cell M{C4emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIKyXmNKdmirYnn0bY9vKG:oIHj1cYFvKERvNUSyUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN7MkeyJO69VQ>? MoLNV2FPT0WU
human A4-Fuk cell MlTMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1f6OmlvcGmkaYTpc44hd2ZiaIXtZY4hSTRvRoXrJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok41OzZ4MjFOwG0> NYS2Om1{W0GQR1XS
human HL-60 cell MnvOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYfaNYdmUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTJ{MUKg{txO Mmr4V2FPT0WU
human NCI-H526 cell NYnjOoJzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NU[4bop5UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUzPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwNUm4NFEh|ryP NUXISW9MW0GQR1XS
human L-363 cell M37Id2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3rWUmlvcGmkaYTpc44hd2ZiaIXtZY4hVC1|NkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlc6OjV{IN88US=> MV\TRW5ITVJ?
human A388 cell NVfvOWlvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3LteGlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFA{QDRizszN MmrCV2FPT0WU
human MS-1 NY\2THMyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJG1UNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkizOFY2KM7:TR?= M3j0cHNCVkeHUh?=
human JAR cell NVG5VYltT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3\yN2lvcGmkaYTpc44hd2ZiaIXtZY4hUkGUIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64OFkzOyEQvF2= NID2c3BUSU6JRWK=
human TI-73 cell NHvtWoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGLhUlFKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4xPjJ{IN88US=> M{fySnNCVkeHUh?=
human CTB-1 cell NWHNVWJET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoPPTY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNVc5OjVizszN NHnXdppUSU6JRWK=
human SK-NEP-1 cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHn2fGNKdmirYnn0bY9vKG:oIHj1cYFvKFONLV7FVE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTFwM{CzPEDPxE1? NFjadWlUSU6JRWK=
human HT-29 cell MlLPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuPVEyOSEQvF2= M1vSPHNCVkeHUh?=
human NCI-H1092 cell MlTsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUC5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjNzODFOwG0> MnrFV2FPT0WU
human KMOE-2 cell M{TJbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4XQWGlvcGmkaYTpc44hd2ZiaIXtZY4hU02RRT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPjF5ODFOwG0> M2q5WXNCVkeHUh?=
human EM-2 cell M1jid2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4rudmlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1MlI5PDFizszN MUTTRW5ITVJ?
human RT-112 cell NISyXodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYPWPXl3UW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPS5|OUi0JO69VQ>? Mnz6V2FPT0WU
human DB cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2HS[mlvcGmkaYTpc44hd2ZiaIXtZY4hTEJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT64OVE{KM7:TR?= MXHTRW5ITVJ?
human NCI-H1770 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHW1dWNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7 M4KxXXNCVkeHUh?=
human CAL-54 cell MnmwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jCcWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzNizszN NXX4UnVSW0GQR1XS
human NB14 cell NU\WR21ET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2rMdmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG3MlY{QTVizszN MoDMV2FPT0WU
human RPMI-7951 cell MmjsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGfIV|lKdmirYnn0bY9vKG:oIHj1cYFvKFKSTVmtO|k2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF7LkG3PFMh|ryP M1vNd3NCVkeHUh?=
human T47D cell M4n3VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3O0fGlvcGmkaYTpc44hd2ZiaIXtZY4hXDR5RDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKxMlIzPDNizszN MVjTRW5ITVJ?
human A549 cell MlXOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFLtO|BKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zQDFzIN88US=> NV3kToVDW0GQR1XS
human A2780 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NULnW3BoUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIyNjh{MkWg{txO MYjTRW5ITVJ?
human SK-MEL-24 cell MkfiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGr0coZKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0zPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTN|LkCzNVEh|ryP MlnxV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products4

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID